clinical trial · NCT06290128
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, ChronicRiliprubartPlaceboRiliprubartPlacebo
brief summary
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
started
Jul 12, 2024
primary completion
May 17, 2027
completion
Nov 20, 2028
last updated
Jun 12, 2026
official title
A Phase 3, Double-blind, Placebo-controlled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol